Investment
Features
FeesSafety
Academy
More
Pluang+

Compare D Wave Quantum Inc (QBTS) vs Stryker Corporation (SYK) Price & Performance

D Wave Quantum IncTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

D Wave Quantum Inc vs Stryker Corporation — how do they compare? D Wave Quantum Inc trades at $14.57 (market cap $5.54B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 19.2× D Wave Quantum Inc's market cap, and Stryker Corporation pays a 1.27% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D Wave Quantum Inc for 32 Days and Stryker Corporation for 21 Days on average.

QBTSSYK
Market Cap
$5.54B$106.24B
Volume
16,671,4522,982,001
Sector
TechnologyHealth
52-Week High
$44.78$388.35
52-Week Low
$12.98$269.75
Typical Hold Time
32 Days21 Days
Enterprise Value
$5.04B$117.70B
Dividend Yield
—1.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

D Wave Quantum Inc

D-Wave Quantum (QBTS) trades at $14.57, down 4.27% today, amid ongoing legal investigations and negative earnings trends. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal severe losses with a -2,001.59% net income margin despite 64.19% gross margins. Recent quarterly earnings have been mixed, missing expectations in two of the last three reported quarters.

Despite unanimous analyst buy ratings and a $34.38 price target suggesting 136% upside, significant execution risks persist. The company faces cash burn challenges with negative operating cash flow and relies heavily on financing activities. Legal investigations and competitive pressures in the quantum computing sector create substantial uncertainty for investors.

Stryker Corporation

Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.

The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

QBTS
90% Buy10% Sell
Avg holding period · 32 Days
SYK

No sentiment data available yet.

Top news

Latest headlines on both assets

About D Wave Quantum Inc

D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.

Read more on QBTS →

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK →